CASE REPORT

Applied multimodal diagnostics in a case of presenile dementia

Sonja Schönecker1*, Matthias Brendel2, Marion Huber1, Christian Vollmar1, Hans-Juergen Huppertz3, Stefan Teipel4,5, Nobuyuki Okamura6, Johannes Levin1,7, Axel Rominger2 and Adrian Danek1

Abstract

Background: Alzheimer’s disease (AD) is the most common cause of dementia in the elderly. The possibility of disease-modifying strategies has evoked a need for early and accurate diagnosis. To improve the accuracy of the clinical diagnosis of AD, biomarkers like cerebrospinal fluid (CSF) and neuroimaging techniques like magnetic resonance imaging (MRI) and positron emission tomography (PET) have been incorporated into the diagnostic guidelines of AD.

Case presentation: In this case report we outline in reference to one of our patients with presenile dementia the current approaches to the diagnosis of AD. The patient was a 59-year old woman presenting with progressive memory decline. CSF-Aβ42 was normal while P-tau was slightly increased. FDG-PET indicated a pattern typical for AD, amyloid-PET showed an extensive global amyloid load, and tau-PET depicted a pronounced hippocampal tracer accumulation. The MRI scan was rated as normal at routine diagnostics, however quantitative volumetric analysis revealed significant atrophy especially of the parietal lobe. The combination of biomarkers and neuroimaging techniques was therefore suggestive of an underlying AD pathology.

Conclusions: To enable early and accurate diagnosis of AD and thereby also patient recruitment for anti-tau or anti-β-amyloid therapeutic trials, a combination of biomarkers and neuroimaging techniques seems useful.

Keywords: Case report, Alzheimer’s disease, Biomarkers, CSF, MRI, FDG-PET, tau-PET, Amyloid-PET

Background

Alzheimer’s disease (AD) is the most common cause of dementia and is estimated to affect 106.8 million people worldwide by the year 2050 [1]. It is clinically characterized by progressive memory and language impairment, functional and behavioral disturbances and visuospatial deficits [2]. A definite diagnosis of AD still relies on post-mortem histopathological detection of intracellular neurofibrillary tangles and extracellular amyloid plaques [3]. It is widely acknowledged that histopathological changes start years before clinical manifestation of the disease [4]. As first disease modifying therapies are approaching early and accurate diagnosis of AD becomes increasingly important [5]. Therefore the National Institute on Aging and the Alzheimer’s Association have revised the criteria for the diagnosis of AD [6]. To assess the probability of an underlying AD pathology biomarkers of the disease and neuroimaging techniques have been incorporated into the diagnostic guidelines of AD. Here we present an exemplary case of presenile dementia based on which we discuss the approaches to the diagnosis of AD.

Case presentation

A 59 year old retired attorney, with 18 years of education presented with a three year history of progressive memory decline. For about one year she hadn’t been able to do the shopping or the cooking. No behavioral changes, language impairment, severe fluctuations of attention and alertness, recurrent visual hallucinations or history of repetitive brain trauma were reported. Family history was positive, her mother as well as an uncle had developed late-onset dementia.

The Mini-Mental-State Examination which had been performed three years ago because of subjective memory impairment had been rated as normal. For neuropsychological testing we applied the CERAD plus battery...
additionally including Trail Making Test A and B as well as verbal fluency tests. The scores of almost all domains of the CERAD plus battery were at least $-1.37$ standard deviations below the age- and education-adjusted norm values. She scored 24 out of 30 points in the Mini-Mental State Examination. Naming (Boston-Naming-test) was intact whereas phonemic verbal fluency was slightly (11 words in 1 min) and semantic fluency (9 words in 1 min) was highly reduced. Memory was highly impaired. She displayed intrusions and showed a reduced performance of word list recall and recognition. Constructional practice was impaired as well. Results of the Trail-Making Test showed reduced visual attention as well as reduced speed of processing. Cognitive flexibility measured by Trail-Making-Test B was also poor. At first presentation the neurological examination was normal. In particular no manifest or latent paresis and no sensory deficit could be detected. Deep tendon reflexes were mildly hypoactive without any pathological reflexes. Cranial nerves were also intact. There was no evidence of extrapyramidal features.

Laboratory tests for metabolic causes of dementia, for example for vitamin B$_{12}$, thyroid, liver and renal function, thiamine level and folate were within the normal range. P-tau (66 pg/ml, N < 61 pg/ml) in cerebrospinal fluid (CSF) was only slightly increased, whereas total Tau (293 pg/ml, N < 500 pg/ml) and Aβ$_{42}$ (1171 pg/ml, N > 500 pg/ml) were normal. All other CSF parameters were within the normal range.

The MRI scan which had been performed three years ago as well as the MRI scan at first presentation were interpreted as normal at visual inspection. Especially no sign of global or regional atrophy could be detected. However, atlas-based volumetric MRI analysis [7, 8] showed a significant reduction especially of temporal and parietal lobe volumes. Z-scores for the hippocampal and parietal lobe volume compared to healthy controls were $-2.9$ and $-4.2$ respectively (Fig. 1).

Moreover, a quantitative analysis based on voxel-wise z-score analysis of patient grey matter segments and grey matter segments from an age and sex-matched control sample after bias correction and spatial normalization in a common standard space following an established method [9] showed a slight asymmetry with more pronounced atrophy of right sided parietotemporal cortical areas (voxel based grey matter reduction $z > -1.96$) (Fig. 2). It has to be noted that for the quantitative analysis, data of the comparison group came from another MRI scanner than the scan of the patient. Acquisition parameters were harmonized between scanners to accommodate possible scanner effects.

Fluorodeoxyglucose-PET (FDG-PET) showed an asymmetric reduction of brain glucose metabolism of parietal and temporal cortical areas with a more pronounced reduction of glucose metabolism in the right hemisphere. In addition glucose metabolism of the posterior cingulate cortex was significantly reduced (Fig. 2).

The patient underwent a florbetaben-PET (FBB-PET) scan which showed extensive FBB retention that was greater in parietotemporal, frontal and posterior cingulate/precuneus cortex and less pronounced in the occipital cortex. Basal ganglia were also slightly affected (Fig. 3).

The tau-PET scan with THK-5351 on the other hand showed high tracer retention in both hippocampi as well as moderately increased tracer retention in parietotemporal cortical areas. There was no elevated tracer retention in other cortical areas (Fig. 3).

Conclusions
As our patient presented with a three year history of cognitive decline that interfered with activities of daily living and scored low in almost all domains of the CERAD plus battery a clinical diagnosis of AD was made [6]. Because of the presenile age at onset and the positive family history a monogenic form of AD might be possible. Genetic testing could have excluded conditions mimicking sporadic AD-like dementia. Our patient however refused genetic testing. Sensitivity and specificity of the clinical diagnosis of AD compared to post-mortem histopathological diagnosis ranges from 70.9 to 87.3 % and from 44.3 to 70.8 % respectively [10]. The combination of biomarkers and neuroimaging techniques was suggestive of an underlying AD pathology. In absence of a neuropathological
confirmation of AD pathology, a definite diagnosis of AD, however, was not possible. The most important alternative diagnosis in a case of presenile dementia are dementia with Lewy bodies (DLB), frontotemporal dementia with memory impairment (FTD) and chronic traumatic encephalopathy (CTE). As our patient had no pronounced variation in attention and alertness, reported no recurrent visual hallucinations and displayed no features of parkinsonism the core features of DLB were not fulfilled [11]. Furthermore no progressive deterioration of personality or social comportment was reported and there was no evidence of progressive language impairment. Therefore there was no clinical evidence for behavioural variant frontotemporal dementia [12] or primary progressive aphasia [13]. As there was no history of recurrent impacts to the head or body, CTE seemed unlikely as well [14]. Table 1 summarizes biomarker and neuroimaging findings in autopsy confirmed cases of DLB, FTD and CTE. [References in Table 1: [15–30]]. In the following the current diagnostic approaches used in the diagnosis of AD are illustrated with reference to our 59-year old patient.

Neuropsychological testing is commonly used as an aid in diagnosing AD. In our patient the scores of almost all domains of the CERAD plus battery were well below average. Memory was most severely affected. As the earliest pathological changes in AD occur in medial temporal lobe structures [31] episodic memory is usually the first cognitive ability to decline, typically followed, like in our case by additional deficits in language and semantic knowledge, executive functions, working memory, attention and visuospatial abilities [32].

Results of laboratory testing for example for vitamin B12, thyroid function, thiamine level and folate, were within the normal range. Laboratory testing should be performed in every AD patient to rule out metabolic causes of dementia. CSF did not suggest malignancy, neuroinflammation or infection. P-tau that reflects the intensity of neuronal degeneration was slightly increased. Interestingly, although amyloid-PET revealed an extensive global amyloid load, CSF-\(\text{A}^{\beta}_{42}\) on the other hand was normal. It has been shown that amyloid load at autopsy of AD patients is inversely correlated to CSF-\(\text{A}^{\beta}_{42}\) whereas tau load is positively correlated to CSF P-tau and total tau [33]. Yet although CSF and amyloid-PET measurements of \(\text{A}^{\beta}_{42}\) are consistent in the majority of patients a dissociation...
| **Table 1** Summary of biomarker and neuroimaging findings in autopsy confirmed DLB, FTD and CTE cases |
|---|---|---|
| **Population** | **CSF biomarker/Ligand** | **Major findings** |
| **CSF** | | |
| Clark et al.[15] | 60 AD, 10 FTD, 3 DLB | total Tau, Aβ42 |
| Slaets et al. [16] | 30 AD, 13 DLB with SP, 5 DLB without SP 30 AD, 9 DLB with NFT, 9 DLB without NFT | P-Tau, total Tau, Aβ42 |
| Koopmann et al. [17] | 95 AD, 18 DLB, 10 FTD | P-Tau, total Tau, Aβ42 |
| Bian et al. [18] | AD 19, FTD 30 | total Tau, Aβ42 |
| Toledo et al. [19] | 71 AD, 29 FTD | P-Tau, total Tau, Aβ42 |
| **MRI** | | |
| Vemuri et al. [20] | 48 AD, 47 FTD, 20 DLB | atrophy pattern in AD: temporoparietal association cortices and medial temporal lobe FTD: frontal and temporal lobes DLB: bilateral amygdalae, dorsal midbrain, inferior temporal lobe |
| Rabinovici et al. [21] | 11 AD, 18 FTD | atrophy in AD: posterior temporoparietal and occipital atrophy atrophy in FTD: medial prefrontal and medial temporal cortex, insula, hippocampus, amygdala |
| Burton et al. [22] | 11 AD, 23 DLB | pronounced medial temporal lobe atrophy in AD compared to DLB patients |
| Kantarci et al. [23] | 2 AD, 3DLB | more pronounced hippocampal atrophy in AD compared to DLB |
| McKee et al. [24] | 1 CTE | generalized cortical atrophy, enlargement of ventricles, cavum septum pellucidum |
| **FDG-PET** | | |
| Minoshima et al. [25] | 10 AD, 4 DLB | AD and DLB: hypometabolism in posterior cingulate, parietotemporal and frontal association cortices additional occipital hypometabolism in DLB |
| Albin et al. [26] | 3 AD-DLB, 3 DLB | compared to AD additional hypometabolism in occipital association and primary visual cortex |
| Kantarci et al. [23] | 2 AD, 3 DLB | low occipital FDG-uptake in 1 AD patient and all DLB patients |
| Foster et al. [27] | 31 AD, 14 FTD | AD: temporoparietal and posterior cingulate hypometabolism FTD: frontal, anterior cingulate and anterior temporal hypometabolism |
| **Amyloid-PET** | | |
| Kantarci et al. [23] | 2 AD, 3 DLB | PIB |
| Bacskai et al. [28] | 1 DLB | PIB |
| Rabinovici et al. [29] | 3 AD, 7 FTD | PIB |
| **Tau-PET** | | |
| Ghetti et al. [30] | 1 FTD | T807 |

CSF cerebrospinal fluid, AD Alzheimer’s disease, FTD frontotemporal dementia, DLB dementia with Lewy bodies, CTE chronic traumatic encephalopathy, SP senile plaque, NFT neurofibrillary tangles, MRI magnetic resonance imaging, PET positron emission tomography, FDG fluorodeoxyglucose
between Aβ_{42} measurements is not uncommon [34]. Especially the combination of CSF biomarkers may increase diagnostic certainty of AD pathology. Yet, as CSF biomarkers do not change during the clinical phase of AD, they cannot be used as markers of disease progression [35]. In comparison to AD patients, DLB and FTD patients present significantly lower P-tau and total tau levels [17]. There is however some overlap in CSF P-tau and total tau between AD, DLB and FTD patients. Aβ_{42} is generally decreased in DLB. Most studies could not define valuable CSF Aβ_{42} cut-off scores for differentiation of DLB from AD [36]. CSF Aβ_{42} levels of FTD patients on the other hand are significantly higher compared to AD patients [18]. The combination of CSF P-tau, total tau and Aβ_{42} has shown high diagnostic sensitivity and specificity in distinguishing AD from DLB and FTD patients. In CTE one would expect normal CSF Aβ_{42} levels and an elevated P-tau/total tau ratio [14]. Large biomarker studies on autopsy confirmed CTE cases however are lacking. As CSF P-tau was only slightly increased while CSF total tau and Aβ_{42} were within the normal range, CSF analysis was not suggestive of an underlying AD pathology in our case.

The MRI scan was interpreted as normal at routine diagnostics, especially no sign of normal-pressure hydrocephalus, cerebrovascular disease, tumours or regional/global atrophy could be detected. Volumetric MRI analysis however revealed significant atrophy of the parietal and temporal lobe, especially of the hippocampus, and may therefore be useful to obtain rater-independent and objective results [7, 8]. Comparison of atrophy patterns can differentiate AD patients with a high sensitivity and specificity from healthy controls and other dementia syndromes like DLB and FTD [20]. In DLB significant gray matter loss is detectable in bilateral amygdalae, the middle temporal lobe as well as the dorsal ponto-mesencephalic junction area [20]. In FTD patients atrophy is normally restricted to the frontal and temporal lobes, with relative sparing of the parietal and occipital lobes. MRI may also be useful to detect neuropathological changes observed in CTE like whole brain atrophy or cavum septum pellucidum with occasional fenestration [24]. In our case volumetric MRI analysis showed a typical AD atrophy pattern with pronounced atrophy of the parietal and temporal lobe, especially the hippocampus, and therefore supported the diagnosis of AD. In Alzheimer’s disease patients, especially hippocampal atrophy (Fig. 1) seems to be highly correlated with episodic memory impairment [37].

In the FDG-PET scan (Fig. 2) the typical AD pattern consisting of a reduction of cerebral glucose metabolism in precuneus, posterior cingulate and parietotemporal association cortices [38] could be detected. In comparison, DLB patients show an additional significant metabolic reduction in the occipital cortex, particularly the primary visual cortex, which distinguishes DLB with a high sensitivity and specificity from AD patients [25]. FTD on the other hand causes hypometabolism in the frontal lobes, the anterior temporal cortex and anterior cingulate cortex [27]. FDG-PET studies that evaluated glucose metabolism in subjects with repetitive brain trauma have shown inconsistent findings [39, 40]. In summary, FDG-PET clearly supported AD as the most probable diagnosis in our case. Like structural MRI, FDG-PET represents a marker of neuronal injury. Retrospective investigations showed a sensitivity of 84 % and a specificity of 74 % for FDG-PET in predicting post-mortem AD pathology at autopsy [41]. FDG-PET thereby outperformed the initial clinical evaluation. Furthermore, FDG-PET seems to be a suitable predictor of conversion to AD in patients with mild cognitive impairment [42].

Amyloid- and tau-PET represent new diagnostic tools. To present a definite diagnosis of AD relies on post-mortem histopathology. Yet these new imaging techniques permit non-invasive visualization and quantification of the two histological hallmarks of the disease.

Amyloid-PET showed a characteristic increase of tracer uptake in cortical regions known to have a high amount of amyloid burden in AD, i.e. frontal, parietal and lateral temporal cortex (Fig. 3). DLB patients can show a similar pattern yet with lower amount of Aβ ligand binding compared with AD patients [43]. FTD patients on the other hand display low cortical tracer retention such that amyloid PET has shown high accuracy in discriminating AD from FTD [44, 45]. Variable degrees of diffuse β-amyloid can be detected in about 47 % of autopsy confirmed CTE cases [46]. Amyloid-PET may therefore differentiate between CTE and AD by identifying different amyloid-deposition patterns. Further studies are needed to determine the topography of β-amyloid depositions in CTE. Showing a high amount of tracer uptake in parietotemporal, frontal and posterior cingulate/precuneus cortex, FBB-PET was suggestive for AD in our case. Recent phase III studies in which the in-vivo uptake of 18-F-labelled amyloid tracers was compared to post-mortem amyloid load showed a sensitivity and specificity of 88 to 92 %, and 88 to 100 % respectively for the detection of amyloid deposits in AD patients [47–49]. As amyloid deposition probably represents a very early event in the course of the disease that occurs years before onset of dementia symptoms, amyloid-PET may allow early and even presymptomatic diagnosis [4].

Increased tau-tracer retention could be detected in parietotemporal cortical areas, especially in the hippocampus (Fig. 3). In contrast to amyloid-PET the sensitivity and specificity of tau-PET imaging have yet to be determined. Post-mortem studies have shown that the amount of tau deposition is highly related to the severity of dementia [50]. In addition to aiding in the early and differential diagnosis of Alzheimer’s disease tau-PET may therefore
serve as a marker of disease progression. Recently, first experiences with tau-PET in DLB were reported [51]. Tau deposition is elevated in some cases of DLB, especially in the inferior temporal region. Tau-PET scans may be positive in some variants of FTD. A first case report of a P301L MAPT mutation carrier showing elevated tau tracer uptake in frontal, anterior temporal and parietal cortex as well as in basal ganglia has been published [30]. Hitherto a single case report of a patient with a clinical diagnosis of CTE who underwent tau-PET imaging has been published [52]. Increased tracer uptake could be detected in globus pallidus, putamen, hippocampus and substantia nigra. Because of increased tracer retention in basal ganglia the detected distribution of tracer retention seemed more suggestive of progressive supranuclear palsy. However the patient did not manifest the typical clinical symptoms of progressive supranuclear palsy. In summary tau-PET also supported a diagnosis of AD in our case.

Overall, although CSF Aβ_{42} was normal, the combination of biomarker and neuroimaging findings in this case was still suggestive of AD pathology. Table 2 rates the biomarker and neuroimaging findings of our case with respect to possible differential diagnosis.

As some of the illustrated diagnostic approaches provided converging evidence, e.g. CSF P-tau, MRI, FDG-PET and Tau-PET each indicated an AD typical neuronal degeneration and thereby provided somewhat redundant information, the necessity for a diagnostic algorithm becomes obvious. A sequential diagnostic process where widely available diagnostic tools like neuropsychological testing to establish the diagnosis of a dementia syndrome and laboratory testing to exclude metabolic causes of dementia are performed in a first step may be useful. Such a baseline testing could help to select patients that profit from further diagnostic work-up. In a second step CSF examination and structural MRI may be rational, on the one hand to further exclude potentially treatable causes of dementia like neuroinflammation or normal pressure hydrocephalus and on the other hand to obtain evidence for an AD-related pathological process and AD typical neuronal degeneration. In patients presenting with an atypical clinical course or atypically early age of onset the more expensive nuclear medicine diagnostic techniques FDG-, amyloid- and tau-PET might be useful to differentiate between AD and important differential diagnoses like pseudo-dementia or frontotemporal dementia. They may also serve as markers of disease progression and prognostic markers. Especially tau and amyloid imaging may furthermore be useful for patient recruitment and serve as a surrogate marker for monitoring the efficacy of future anti-tau or anti-amyloid strategies.

### Table 2 Rating of biomarker and neuroimaging findings of our case with respect to possible differential diagnosis

| Biomarker/neuroimaging findings | AD | FTD | DLB | CTE |
|---------------------------------|----|-----|-----|-----|
| CSF P-tau                       | +  | -   | -   | -   |
| CSF Aβ_{42}                     | -  | O   | O   | O   |
| MRI - clinical routine          | O  | O   | O   | O   |
| MRI - voxel-based               | ++ | -   | +   | -   |
| FDG-PET                         | ++ | -   | O   | -   |
| amyloid-PET                     | ++ | -   | +   | +   |
| tau-PET                         | ++ | O   | O   | O   |

++ highly increases probability, + increases probability, O probability unchanged, – decreases probability

### Abbreviations

AD, Alzheimer’s disease; CSF, cerebrospinal fluid; CTE, chronic traumatic encephalopathy; DLB, dementia with Lewy bodies; FBB, florbetaben; FDG, fluorodeoxyglucose; FTD, frontotemporal dementia; MRI, magnetic resonance imaging; PET, positron emission tomography

### Funding

No funding was obtained.

### Availability of data and materials

All data are presented in the manuscript. There are no additional data.

### Authors’ contributions

SS coordinated and drafted the manuscript and figures; MB, CV, HJH, ST, NO, AR were involved in imaging acquisition and analyses; MH was involved in patient care; MB, MH, CV, HJH, ST, AR, JL, NO, AD critically revised the manuscript. All authors read and approved the final manuscript.

### Competing interests

The authors declare that they have no competing interests.

### Consent for publication

Written informed consent for publication of this Case Report and any accompanying images was obtained from the patient’s next of kin, i.e. her husband. A copy of the written consent is available for review to the Editor of this journal.

### Ethics approval and consent to participate

Not applicable.

### Author details

1. Department of Neurology, Ludwig-Maximilians University, Munich, Germany.
2. Department of Nuclear Medicine, Ludwig-Maximilians University, Munich, Germany.
3. Swiss Epilepsy Center, Zurich, Switzerland.
4. Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany.
5. German Center for Neurodegenerative Diseases, Rostock, Germany.
6. Department of Pharmacology, Tohoku University School of Medicine, Sendai, Japan.
7. German Center for Neurodegenerative Diseases, Munich, Germany.

Received: 2 March 2016 Accepted: 26 July 2016
Published online: 09 August 2016

### References

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s & Dementia. 2007;3(3):186–91.
2. Cummings JL. Alzheimer’s Disease. The New England journal of medicine. 2004;351:56–67.
3. Jellinger KA. Neuropathology of Dementia Disorders. Journal of Alzheimer’s Disease & Parkinsonism. 2014;4:15.
4. Bateman RJ, Xiong C, Berzinger TLS, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Kie X, Blazey TM, et al. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease. New England Journal of Medicine. 2012;367(9):795–804.
5. Bergmans BA, De Strooper B. y-secretases: from cell biology to therapeutic strategies. The Lancet Neurology. 2010;9(2):215–26.

6. Mckhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koriolietz WJ, Manly JJ, Mayeux R. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia. 2011;7(3):263–9.

7. Huppert H-J, Kroell-Seger J, Kloeppel S, Ganz RE, Kaseubek J. Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures. NeuroImage. 2010;49(3):2166–24.

8. Frings L, Yew B, Flanagan E, Lam BY, Hull M, Huppert HJ, Hodges JR, Homburger M. Longitudinal grey and white matter changes in frontotemporal dementia and Alzheimer's disease. PLoS one. 2014;9(3)e9814.

9. Teipel SJ, Reuter S, Stettjes B, Acosta-Cabronero J, Emmann U, Fellgiebel A, Filippi M, Frisoni G, Hentschel F, Jessen F, et al. Multicenter stability of diffusion tensor imaging measures: a European clinical and physical phantom study. Psychiatry research. 2011;194(3):363–71.

10. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of dementia pathology using structural MRI: differential-STAND. NeuroImage. 2011;55(2):522–31.

11. McKeith IG, Dickson DW, Lowe J, Emre M, O' Ballard C, Dickson DW, Farlow M, Weitlauf SL. Cerebrospinal fluid tau and -amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Archives of neurology. 2003;60(12):1696–702.

12. Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S. Amyloid pathology and its variants. Neurology. 2011;76(10):1006–14.

13. Montenigro PH, Baugh CM, Daneshvar DH, Mez J, Budson AE, Au R, Katz DI, Cantu RC, Stern RA. Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed diagnostic criteria for traumatic encephalopathy syndrome. Alzheimers Res Ther. 2014;6(5):68.

14. Clark CM, Xie S, Chittiams J, Evbodan D, Peskind E, Galasko D, Morris JC, McKeel DW, Farlow M, Weitlauf SL. Cerebrospinal fluid tau and -amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Archives of neurology. 2003;60(12):1696–702.

15. Slaets S, Le Bastard N, Theunis J, Sleegers K, Verstraeten A, De Leenheer E, Luyckx J, Martin JJ, Van Broeckhoven C, Engelsborg S. Amyloid pathology influences aβ1–42 cerebrospinal fluid levels in dementia with Lewy bodies. Journal of Alzheimer's Disease. 2013;33(1):137–46.

16. Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelsborg S. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochemistry international. 2009;55(5):214–8.

17. Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, Moore P, de Koning I, Clark CM, Rosso S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology. 2008;70(19 Pt 2):1827–35.

18. Toleda JB, Brettecheider J, Grossman M, Arnold SE, Hu WT, Xie SX, Lee VM-Y, Shaw LM, Trojanowksi JQ. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta neuropathologica. 2012;124(1):23–35.

19. Vemuri P, Simon G, Kantarci K, Whitwell JL, Senjem ML, Przybelski SA, Gunter JL, Josephs KA, Knopman DS, Boeve BF, et al. Antemortem magnetic resonance imaging add to a clinical diagnosis of dementia with Lewy bodies. Radiology. 2010;257(1):26–34.

20. Rascovsky K, Hodges JR, Knopman D, Mendez M, Kramer JH, Neuhause J, van Swieten JC, Leight S, Massimo L, Wood E, Forman M, Moore P, Johnson KA, Dickerson BC, Goedert M. Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleonic for neuropathology and neuroimaging. Neuropsychology and applied neurobiology. 2015;41(1):24–46.

21. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta neuropathologica. 1991;82(4):239–59.

22. Rabinovici GD, Holm R, Alkalay A, Fournier A, Garzon R, Drayer D, Brown MA, Otey WE, Hoffman DR, et al. The role of amyloid PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77(23):1404–22.

23. Kantarcioğlu K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA, Dickson DW, Parisi JE, Knopman DS, Smith GE. Multimodality imaging characteristics of dementia with Lewy bodies. Neurology. 2009;72(5):390–9.

24. McKee AC, Cantu RC, Nowinski CJ, Hadley-Whynne ET, Gavett BE, Budde AE, Santini VE, Lee HS, Kubilus CA, Stern RA. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. Journal of neuropathology and experimental neurology. 2009;68(7):709–35.

25. Minoshima S, Foster NL, Sia MA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Annals of neurology. 2001;50(3):358–65.

26. Albin R, Minoshima S, D'Amato C, Frey K, Kuhl D, Sia F. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology. 1996;47(2):462–6.

27. Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, DeCarli CS, Turner RS, Koeppen RA, Higdon R, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007;130(Pt 10):2616–35.

28. Backsai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, Izray CN, Klunk WE, Mathis CA, Dekosky ST. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Archives of neurology. 2007;64(3):431–4.

29. Rabinovici GD, Rosen H, Alkalay A, Kornak J, Furst A, Agarwal N, Mornino E, O'Neil J, Janabi M, Kaydasy A. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77(23):1404–22.

30. Hiett MJ, Robert M. Tau and amyloid PET imaging: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Archives of neurology. 2003;60(12):1696–702.

31. Rabinovici GD, Holm R, Alkalay A, Fournier A, Garzon R, Drayer D, Brown MA, Otey WE, Hoffman DR, et al. The role of amyloid PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77(23):1404–22.

32. Mollenhauer B, Bibl M, Wittfogel J, Steinacker P, Ciesielczyk B, Neubert K, et al. BMC Neurology. 2016;16:131.

33. Hiett MJ, Robert M. Tau and amyloid PET imaging: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Archives of neurology. 2003;60(12):1696–702.

34. Rabinovici GD, Holm R, Alkalay A, Fournier A, Garzon R, Drayer D, Brown MA, Otey WE, Hoffman DR, et al. The role of amyloid PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77(23):1404–22.

35. Mollenhauer B, Bibl M, Wittfogel J, Steinacker P, Ciesielczyk B, Neubert K, et al. BMC Neurology. 2016;16:131.
43. Donaghy P, Thomas AJ, O’Brien JT. Amyloid PET Imaging in Lewy body disorders. The American journal of geriatric psychiatry. 2015;23(1):23–37.

44. Rowe C, Ng S, Ackermann U, Gong S, Pike K, Savage G, Cowie T, Dickinson K, Maruff P, Darby D. Imaging β-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718–25.

45. Engler H, Santillo AF, Wang SX, Lindau M, Svitcheva I, Nordberg A, Lammfelt L, Langstrom B, Kilander L. In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging. 2008;35(1):100–6.

46. McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, Lee HS, Wojtowicz SM, Hall G, Baugh CM, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136(Pt 1):43–64.

47. Curtis C, Ganez JF, Singh J, Sabagh MN, Villena T, Sabagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA neurology. 2015;72(3):287–94.

48. Sabri O, Sabagh MN, Seibyl J, Barthel H, Akatsu H, Uchi Y, Sendt K, Murayama S, Ishi K, Takao M. Florbetapir PET imaging to detect amyloid beta plaques in Alzheimer disease. Phase 3 study. Alzheimer’s & Dementia. 2015;11(8):964-74.

49. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Fleisher AS, Reiman EM, Sabagh MN, Sadowsky CH, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. The Lancet Neurology. 2012;11(8):669–78.

50. Nelson PT, Alafuzoff I, Riggs B, Machac J, Delman B, Goldstein M, Jennings D, D’Antonio E, Martin J, et al. Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathy: studies of a retired NFL player and of a man with FTD and a severe head injury. Translational psychiatry. 2014;4:e441.

51. Minoshima S, Frey KA, Koeppke RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. Journal of Nuclear Medicine. 1995;36(7):1238–48.